公开(公告)号：WO2023067628A1

公开(公告)日：2023-04-27

申请号：PCT/IN2022/050940

申请日：2022-10-20

Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)

Inventor： DEB, Indubhusan ,  BHOWMIK, Arup

IPC: C07D209/00 ,  A61K31/46 ,  C07D451/04

Abstract: The present invention provides a new synthetic method for the preparation of building block indole-3-carboxylic acid (ICA) derivatives used as a key starting material to produce several artificial drugs. An efficient, safe, operationally simple, cost-effective method for the preparation of several ICA derivatives has been introduced in a very simple way. Utilizing easily available starting material, reagent, and solvent several key starting materials of ICA derivatives have been synthesized rapidly indicates the novel method is functional group tolerable. The preparation process does not involve use of any reducing agents or transition metals in the economically viable and operationally simple condition in one pot. ICA derivatives have been generated from isatin derivative in one step and this methodology is important with a wide range of applications from the drug development and material synthesis point of view.

公开(公告)号：WO2023039104A1

公开(公告)日：2023-03-16

申请号：PCT/US2022/042959

申请日：2022-09-08

Applicant: KINDEVA DRUG DELIVERY L.P.

Inventor： COCKS, Philip ,  WRIGGLESWORTH, Sarah ,  MCCORMACK, Connor ,  LISTER, James ,  HARRISON, Lauren

IPC: A61K9/12 ,  A61K47/10 ,  A61K47/06 ,  A61K31/137 ,  A61K31/56 ,  A61K31/58 ,  A61K9/00 ,  A61M15/00 ,  A61K31/40 ,  A61K31/439 ,  A61K31/46 ,  A61K47/12

Abstract: A composition comprising a solution comprising an active pharmaceutical ingredient comprising an anticholinergic agent, such as ipratropium bromide, and a propellant comprising HFA-152a, HFO-1234ze(E), or both. A metered dose inhaler comprising a metering valve a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises said composition.

公开(公告)号：WO2023006248A2

公开(公告)日：2023-02-02

申请号：PCT/EP2022/025353

申请日：2022-07-26

Applicant: ROQUETTE FRERES

Inventor： LEFRANC-MILLOT, Catherine ,  VIDAL, Hubert ,  DEFOIS, Clémence

IPC: A61K36/48 ,  A61K38/01 ,  A61K31/42 ,  A61K31/46 ,  A61K31/575 ,  A61P1/16 ,  A61P21/00 ,  A23J1/14 ,  A23J3/14 ,  A23J3/34 ,  A23L33/185 ,  A23J3/346 ,  A61K38/011

Abstract: La présente invention consiste en une composition de protéines de légumineuse, préférentiellement de pois ou de féverole, dont le degré d'hydrolyse est inférieur à 10%, en particulier pour une utilisation thérapeutique, de préférence dans la prévention et/ ou le traitement d'une maladie susceptible d'être traitée par une activation de la synthèse du FGF19 choisie parmi la sarcopénie ou la stéatohépatite non alcoolique.

公开(公告)号：WO2022246405A1

公开(公告)日：2022-11-24

申请号：PCT/US2022/072374

申请日：2022-05-17

Applicant: KARUNA THERAPEUTICS, INC.

Inventor： FELDER, Christian

IPC: A61K31/46 ,  A61K31/4439 ,  A61K45/06 ,  A61P25/18

Abstract: Provided is a method of treating a central nervous system disorder in a patient in need thereof, the method comprising co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising an antipsychotic. In certain embodiments, a method of treating schizophrenia in a patient in need thereof is provided. For example, the method comprises co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising risperidone or aripiprazole. In certain embodiments, the first composition comprising xanomeline and/or a salt thereof further comprises an anticholinergic agent, such as a muscarinic antagonist.

公开(公告)号：WO2022238250A1

公开(公告)日：2022-11-17

申请号：PCT/EP2022/062271

申请日：2022-05-06

Applicant: WARSZAWSKIE ZAKŁADY FARMACEUTYCZNE POLFA S.A.

Inventor： PIETRZAK, Tomasz ,  CEBULSKA, Ewelina ,  ŁUCZYŃSKI, Paweł ,  MAGNUSZEWSKA, Monika

IPC: A61K9/08 ,  A61K47/12 ,  A61K31/46 ,  A61P27/10 ,  A61K9/0048

Abstract: The present invention is related to a preservative free ophthalmic low concentration atropine sulfate composition containing atropine sulfate in an amount from about 0.005 w/w% to about 0.05 w/w%, citrate buffer, a tonicity agent and water, having a pH from about 4.0 to about 5.5. Optionally this composition can also contain other excipients such as a pH adjuster, a chelating agent, a complexing agent, and/or a viscosity agent. The invention also relates to a process for the preparation of this composition and its use in the treatment and/or prevention of myopia, preferably in a paediatric population.

公开(公告)号：WO2022189366A1

公开(公告)日：2022-09-15

申请号：PCT/EP2022/055775

申请日：2022-03-07

Applicant: HEPTARES THERAPEUTICS LIMITED

Inventor： TASKER, Tim

IPC: A61K31/445 ,  A61K31/46 ,  A61P25/28

Abstract: This invention relates to the use of compounds which are agonists of the muscarinic M1 receptor and M4 receptor, their salts and pharmaceutical compositions containing them in therapy of the human body. In particular, the invention is directed to compounds, which are useful in the treatment of diseases mediated by the muscarinic M1/M4 receptors, including neurodegenerative disorders (i.e. Alzheimer's disease) and neuropsychiatric disorders (Schizophrenia).

公开(公告)号：WO2022115526A1

公开(公告)日：2022-06-02

申请号：PCT/US2021/060720

申请日：2021-11-24

Applicant: VANDA PHARMACEUTICALS INC.

Inventor： POLYMEROPOULOS, Mihael ,  HE, Yunsheng ,  POLYMEROPOULOS, Christos

IPC: A61K31/46 ,  A61P25/22

Abstract: Disclosed herein is a method of treatment or prevention of public speaking anxiety (PSA), which may in some cases present as a symptom of social anxiety disorder (SAD), including the performance only (SAD-PO) subtype of SAD. The method of treatment includes administering an α7 nAChR agonist such as (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane to the individual at a therapeutically effective dose.

公开(公告)号：WO2022051321A1

公开(公告)日：2022-03-10

申请号：PCT/US2021/048594

申请日：2021-09-01

Applicant: COHERUS BIOSCIENCES, INC.

Inventor： COOK, Charles M.

IPC: A61K31/47 ,  A61P1/16 ,  A61K31/166 ,  A61K31/343 ,  A61K31/42 ,  A61K31/46 ,  A61K31/575 ,  A61K45/06 ,  A61K9/24

Abstract: Provided herein are fixed dose combination formulations useful for the treatment of PPARγ-mediated diseases or disorders. In particular, provided herein are fixed dose combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a FXR agonist, or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of making and methods of using the fixed dose combination formulations.

公开(公告)号：WO2022048561A1

公开(公告)日：2022-03-10

申请号：PCT/CN2021/115900

申请日：2021-09-01

Applicant: 成都第一制药有限公司

Inventor： 刘昭华 ,  曾烨

IPC: A61K31/46 ,  A61P9/14 ,  A61P9/12 ,  A61P9/10 ,  A61P9/00

Abstract: 山莨菪碱或其药学上可接受的盐在制备细胞糖萼保护剂中的应用，山莨菪碱或其药学上可接受的盐作为细胞糖萼保护剂在恢复和保护细胞糖萼以及细胞黏附粘接中的作用。山莨菪碱或其药学上可接受的盐在制备细胞糖萼保护剂中的应用还具备保护内皮细胞结构和功能的作用。

公开(公告)号：WO2021233461A1

公开(公告)日：2021-11-25

申请号：PCT/CN2021/098056

申请日：2021-06-03

Applicant: 苏州晶云药物科技股份有限公司

Inventor： 鲁霞 ,  张晓宇

IPC: C07D451/06 ,  A61K31/46 ,  A61P1/18

Abstract: 本发明涉及苯并噻唑类化合物的新晶型及其制备方法。本发明提供了式(I)化合物的晶型A及其制备方法和用途。本发明提供的式(I)化合物晶型A，在溶解度、熔点、稳定性、溶出度、引湿性、黏附性、流动性、生物有效性以及加工性能、提纯作用、制剂生产、安全性等方面中的至少一方面上存在优势，为含式(I)化合物的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。